|
US2019375731A1
|
|
Prodigiosin analogs and methods of use
|
|
US2018243306A1
|
|
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
US2019381054A1
|
|
Inhibitors of HIV-1 integrase multimerization
|
|
US2018100167A1
|
|
Methods for enriching gene-targeted cells
|
|
US2018080942A1
|
|
Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein
|
|
US2017335342A1
|
|
P21-activated kinase inhibitor domain targeted transgenic mouse
|
|
US2016354339A1
|
|
Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors
|
|
US2016101111A1
|
|
Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
|
|
US2017283402A1
|
|
Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD
|
|
US2016097083A1
|
|
Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
|
|
US2017073759A1
|
|
Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
|
|
US2015164934A1
|
|
Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
|
